Q32 Bio Inc（QTTB）資訊與事件QTTBQ32 Bio Inc

Major Averages Decline Amid Rising Geopolitical Tensions

The major averages were broadly lower as rising geopolitical tensions and another bout of semiconductor selling weigh on risk sentiment. President Donald Trump said he was reinstating a blockade on Iranian shipping through the Strait of Hormuz, even going so far in a social media post as to call the U.S. the "Guardian of the Hormuz Strait." Oil prices surged after the news, reviving concerns that higher energy costs could complicate the inflation outlook.Meanwhile, this week marks the unofficial start of second-quarter earnings season, with major U.S. banks set to report over the next several days. Investors also have an eye on upcoming June CPI and retail sales data, along with congressional testimony from Federal Reserve Chair Kevin Warsh.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Appleis suing OpenAI, accusing the ChatGPT maker and its hardware chief Tang Tan of engaging in a coordinated effort to steal secret trade information about upcoming products,MGM Resortshas been in talks over a potential deal with Barry Diller's People Incorporatedafter the media mogul offered to acquire the casino giant,Williamsin its Power Innovation joint venture from BlackstoneFirst HawaiianTriCo Bancsharesin an all-stock transactionShellSprng Energy to Aditya Birla Renewables for $1.8B2. WALL STREET CALLS:Shopifyto Buy from Hold at JefferiesBofAPapa John'sto Underperform, says management turnover raises uncertaintyAmerican Expressto Overweight from Neutral at JPMorganTravelersto Sell from Hold at TD CowenDeckers Outdoorto Buy from Hold at Jefferies3. AROUND THE WEB:Multiple states, including California, are expected to file suit today to challenge the Paramountand Warner Bros.deal, sources told CNBC's David FaberGoogleis expanding sales of its AI TPUs to external cloud providers as a lower-cost, more reliable alternative to NvidiaGPUs, intensifying competition even as Nvidia remains the dominant supplier of AI infrastructure, Information reportsDisney'slive-action "Moana" was set to collect $43M at the domestic box office from Thursday to Sunday, but originally the company had been aiming for $60M or more, NY Times reportsAT&Twill pay $184.1M to settle a lawsuit accusing the company of shortchanging 300,000 employees out of pension payments, Reuters reportsSK HynixCEO Kawk Noh-jung said he believes the global memory industry is heading into its "worst year" during its supply shortage in 2027, with the demand for memory continuing to exceed the company's ability to produce it, Reuters says4. MOVERS:Q32 Biohigher after reporting 36-week topline results from itsConmedgains afterthe company is weighing its options amid takeover interest from private equity firmsZoomInfoincreases afterOn Semifalls after TD Cowenon the stockIonis Pharmaceuticals (IONS) lower afterin its Phase 1-2 ASCEND study5. EARNINGS/GUIDANCE:Hillman Solutionsand backed its guidance for FY26LogProstyle, with EPS lower year-over-yearASMLon July 15TSMCon July 16JPMorgan Chaseon July 14INDEXES:Near midday, the Dow was down 0.20%, or 106.78, to 52,530.23, the Nasdaq was down 1.03%, or 270.88, to 26,010.73, and the S&P 500 was down 0.46%, or 34.47, to 7,540.92.

Q32 Bio Announces Bempikibart Clinical Trial Results

Q32 Bio announced 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA. Bempikibart is a fully human anti-IL-7Ralpha antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling. The Part B portion of the SIGNAL-AA program is an open-label clinical trial building upon the previously completed Part A, which established proof-of-concept of bempikibart in AA. In Part B, bempikibart is being evaluated in 33 patients with severe or very severe AA with a maximum duration of current episode of four years. Enrollment amongst patients with prior exposure to JAK inhibitor therapy were allowed; amongst the 33 enrolled patients, 36.4% had previously been treated with oral JAK inhibitors. Total enrollment exceeded the initial target due to patient demand. In Part B, patients are treated with bempikibart for 36 weeks, with off-drug follow-up through Week 52 before optional enrollment in the open-label extension. Dosing includes an initial loading regimen of 200mg of bempikibart dosed weekly for four doses, followed by continued dosing of 200mg every-other-week over a 32-week period, for a total dosing period of 36 weeks. Across both regimens, bempikibart was administered subcutaneously. The prespecified primary efficacy analysis was evaluated on the basis of mean percentage change from baseline in SALT scores in the modified intent-to-treat population. Additional prespecified efficacy analyses included the proportion of patients achieving various relative and absolute SALT improvements including SALT-20, SALT30, and SALT50 responses at Week 36, with follow-up through Week 52. Mean percent reduction in SALT score from baseline of 35.3% in the mITT analysis. Overall, 40% of patients in the mITT analysis and 30.3% of patients in the intent-to-treat analysis achieved a SALT-20 response. Achievement of a SALT-20 response was observed in patients with both severe and very severe disease. Also, 44% of patients in the mITT analysis and 33.3% of patients in the ITT analysis achieved SALT30 response. While 44% of patients in the mITT and 33.3% of patients in the ITT analysis achieved SALT50 response. Early signs of durability in the off-drug period include maintenance or deepening of response in multiple patients including one who achieved complete hair growth. Bempikibart was observed to have a generally well-tolerated safety profile in SIGNAL-AA Part B, consistent with prior studies. No new safety signals were observed. There were no serious adverse events or Grade 3 or higher adverse events related to treatment. The most common treatment-emergent adverse event was injection site reaction which were primarily singular events, with ISR incidence of 4% across all Part B dose administrations. All ISRs reported were mild and resolved with no intervention, with the majority resolving within a day. Bempikibart demonstrated a favorable pharmacokinetic, pharmacodynamic and anti-drug antibody profile in Part B. PK data from Part B support the loading dose regimen had its intended effect, achieving steady state concentrations approximately 10 weeks earlier than in Part A. Negligible ADA was observed in Part B.